PL3626736T3 - Sposób wytwarzania rekombinowanego vwf o dużej masie cząsteczkowej w hodowli komórkowej - Google Patents

Sposób wytwarzania rekombinowanego vwf o dużej masie cząsteczkowej w hodowli komórkowej

Info

Publication number
PL3626736T3
PL3626736T3 PL19191438.1T PL19191438T PL3626736T3 PL 3626736 T3 PL3626736 T3 PL 3626736T3 PL 19191438 T PL19191438 T PL 19191438T PL 3626736 T3 PL3626736 T3 PL 3626736T3
Authority
PL
Poland
Prior art keywords
molecular weight
cell culture
high molecular
producing recombinant
weight vwf
Prior art date
Application number
PL19191438.1T
Other languages
English (en)
Inventor
Leopold Grillberger
Manfred Reiter
Wolfgang Mundt
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44514323&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3626736(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of PL3626736T3 publication Critical patent/PL3626736T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL19191438.1T 2010-07-08 2011-07-08 Sposób wytwarzania rekombinowanego vwf o dużej masie cząsteczkowej w hodowli komórkowej PL3626736T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36263510P 2010-07-08 2010-07-08

Publications (1)

Publication Number Publication Date
PL3626736T3 true PL3626736T3 (pl) 2025-10-13

Family

ID=44514323

Family Applications (5)

Application Number Title Priority Date Filing Date
PL16153131.4T PL3064508T5 (pl) 2010-07-08 2011-07-08 Sposób wytwarzania rekombinowanego vwf o dużej masie cząsteczkowej w hodowli komórkowej
PL19191438.1T PL3626736T3 (pl) 2010-07-08 2011-07-08 Sposób wytwarzania rekombinowanego vwf o dużej masie cząsteczkowej w hodowli komórkowej
PL11736502T PL2590998T3 (pl) 2010-07-08 2011-07-08 SPOSÓB WYTWARZANIA REKOMBINOWANEGO vWF O DUŻEJ MASIE CZĄSTECZKOWEJ W HODOWLI KOMÓRKOWEJ
PL18175765T PL3392271T3 (pl) 2010-07-08 2011-07-08 Sposób otrzymywania rekombinowanego adamts13 w linii komórkowej
PL11738351T PL2591094T3 (pl) 2010-07-08 2011-07-08 Sposób otrzymywania rekombinowanego adamts13 w linii komórkowej

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL16153131.4T PL3064508T5 (pl) 2010-07-08 2011-07-08 Sposób wytwarzania rekombinowanego vwf o dużej masie cząsteczkowej w hodowli komórkowej

Family Applications After (3)

Application Number Title Priority Date Filing Date
PL11736502T PL2590998T3 (pl) 2010-07-08 2011-07-08 SPOSÓB WYTWARZANIA REKOMBINOWANEGO vWF O DUŻEJ MASIE CZĄSTECZKOWEJ W HODOWLI KOMÓRKOWEJ
PL18175765T PL3392271T3 (pl) 2010-07-08 2011-07-08 Sposób otrzymywania rekombinowanego adamts13 w linii komórkowej
PL11738351T PL2591094T3 (pl) 2010-07-08 2011-07-08 Sposób otrzymywania rekombinowanego adamts13 w linii komórkowej

Country Status (25)

Country Link
US (8) US9458222B2 (pl)
EP (7) EP3626736B1 (pl)
JP (3) JP6138683B2 (pl)
KR (4) KR102027991B1 (pl)
CN (4) CN103097522A (pl)
AU (6) AU2011274467B2 (pl)
BR (2) BR112013000515B1 (pl)
CA (2) CA2804275A1 (pl)
CO (2) CO6690745A2 (pl)
DK (4) DK3064508T4 (pl)
EA (5) EA202090220A3 (pl)
ES (5) ES2761692T5 (pl)
FI (2) FI3626736T3 (pl)
HR (4) HRP20180136T1 (pl)
HU (3) HUE046443T2 (pl)
IL (5) IL286298B (pl)
MX (3) MX339632B (pl)
NZ (2) NZ605404A (pl)
PL (5) PL3064508T5 (pl)
PT (4) PT3626736T (pl)
SG (3) SG186936A1 (pl)
SI (4) SI3626736T1 (pl)
TR (1) TR201815211T4 (pl)
TW (4) TWI617575B (pl)
WO (2) WO2012006591A1 (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2358895B1 (en) 2008-12-05 2018-05-30 Baxalta GmbH Methods of measuring adamts13-mediated in vivo cleavage of von willebrand factor and uses thereof
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
CN103097522A (zh) * 2010-07-08 2013-05-08 巴克斯特国际公司 在细胞培养物中生产重组adamts13的方法
EP3858375B1 (en) * 2011-06-10 2024-03-20 Takeda Pharmaceutical Company Limited Treatment of coagulation disease by administration of recombinant vwf
US9030963B2 (en) * 2012-12-03 2015-05-12 Honeywell International Inc. Analyzing a network topology
UY35343A (es) * 2013-02-26 2014-09-30 Bayer Healthcare Llc Formulaciones y procedimientos para la producción de proteína recombinante aumentada
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US20140271622A1 (en) * 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
AU2013203062C1 (en) 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
ES2924393T3 (es) 2014-04-16 2022-10-06 Inst Nat Sante Rech Med Anticuerpos para la prevención o el tratamiento de episodios hemorrágicos
US10829539B2 (en) * 2014-06-13 2020-11-10 Csl Limited Production of recombinant von Willebrand factor in a bioreactor
MA41685A (fr) * 2014-10-17 2017-08-22 Biogen Ma Inc Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
CA2973343C (en) * 2015-02-05 2023-08-08 R.P. Scherer Technologies, Llc Activated formylglycine-generating enzymes and methods of producing and using the same
AR104050A1 (es) * 2015-03-26 2017-06-21 Chugai Pharmaceutical Co Ltd Proceso de producción con iones de cobre controlados
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
CN116159130B (zh) 2016-08-04 2025-09-09 武田药品工业株式会社 使用adamts13治疗、改善和/或预防镰状细胞病、急性肺损伤和/或急性呼吸窘迫综合征中的血管阻塞危象
CN106957815B (zh) * 2017-03-16 2021-05-07 杨涛 一种用于人类多潜能干细胞的无血清培养基的配方
AU2018298233B2 (en) 2017-07-07 2025-04-24 Takeda Pharmaceutical Company Limited Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant VWF
FI3648787T3 (fi) 2017-07-07 2025-01-20 Takeda Pharmaceuticals Co Elektiiviseen leikkaustoimenpiteeseen osallistuvien vaikeaa von willebrandin tautia sairastavien potilaiden hoito antamalla rekombinanttia vwf:ää
JP2021519280A (ja) 2018-03-21 2021-08-10 バクスアルタ インコーポレイテッド クロマトグラフィー法によるｖｗｆとｖｗｆプロペプチドの分離
CA3128498A1 (en) 2019-02-01 2020-08-06 Bjorn Mellgard Methods of prophylactic treatment using recombinant vwf (rvwf)
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US10961500B1 (en) 2019-04-23 2021-03-30 Regeneron Pharmaceuticals, Inc. Cell culture medium for eukaryotic cells
EP4028046B1 (en) 2019-09-11 2024-02-14 Takeda Pharmaceutical Company Limited Methods of treatment related to complexes of von willebrand factor and complement c1q
WO2021067668A1 (en) 2019-10-04 2021-04-08 The Children's Medical Center Corporation Adamts13 treatment to enhance graft survival
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
WO2021158777A1 (en) 2020-02-04 2021-08-12 Baxalta Incorporated Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf
WO2021234458A1 (en) 2020-05-22 2021-11-25 Takeda Pharmaceutical Company Limited Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767704A (en) * 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
NL8500961A (nl) 1985-04-01 1986-11-03 Stichting Vrienden Van De Stic Cdna-codering voor de humane von willebrand-factor, plasmiden met een dergelijke cdna-codering respektievelijk fragmenten ervan, alsmede micro-organismen, welke dergelijke plasmiden bevatten.
WO1986006096A1 (en) 1985-04-11 1986-10-23 The Children's Medical Center Corporation Von willebrand factor
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
ES2323490T3 (es) 1994-11-10 2009-07-17 Baxter Healthcare Sa Procedimiento de produccion de agentes biologicos en un medio de cultivo sin proteinas.
DE69608668T2 (de) 1995-02-23 2001-02-01 Quest International B.V., Naarden Peptide für gewebe- und zellkulturmedien
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP0953041A4 (en) 1996-08-30 2003-01-29 Life Technologies Inc SERUM-FREE CULTURAL MEDIUM FOR MAMMAL CELLS AND THEIR USE
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6103529A (en) 1996-10-10 2000-08-15 Life Technologies, Inc. Animal cell culture media comprising peptides derived from rice
WO1998041611A1 (en) 1997-03-20 1998-09-24 Regents Of The University Of Minnesota Process for the continuous culture of cells
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6528286B1 (en) * 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6406909B1 (en) 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
JP2001120262A (ja) * 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
US6926894B2 (en) * 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
NZ533084A (en) * 2001-11-28 2006-02-24 Sandoz Ag Cell culture process
US20050084928A1 (en) * 2002-01-17 2005-04-21 Birch John R. Glutamine-auxothrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium
US20050084828A1 (en) 2003-10-21 2005-04-21 The University Of North Carolina At Chapel Hill Apparatus and method for braille instruction
EP1593388A1 (en) 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
TWI384069B (zh) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US20060094104A1 (en) * 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
US8273553B2 (en) * 2004-11-02 2012-09-25 Ares Trading S.A. Production of growth hormone in serum-free cell culture medium for mammalian cells
DE602005026548D1 (de) 2004-11-02 2011-04-07 Ares Trading Sa Serumfreies kulturmedium für säugerzellen
US20070049557A1 (en) 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
KR101423344B1 (ko) * 2006-01-04 2014-07-30 백스터 인터내셔널 인코포레이티드 올리고펩티드-무함유 세포 배양 배지를 이용하여 단백질을 발현시키는 방법
US20070190057A1 (en) * 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
CN101490239A (zh) * 2006-07-14 2009-07-22 帝斯曼知识产权资产管理有限公司 改进的细胞培养方法
CA2842964A1 (en) * 2006-09-13 2008-03-20 Abbvie Inc. Cell culture improvements
US7960869B2 (en) 2006-09-22 2011-06-14 Siemens Industry, Inc. Internal intelligence for remote operated relay
CA2671676C (en) * 2006-12-27 2014-04-22 Baxter Healthcare Sa Von willebrand factor-and factor viii-polymer conjugates having a releasable linkage
US9012180B2 (en) * 2007-03-02 2015-04-21 Wyeth Llc Use of copper and glutamate in cell culture for production of polypeptides
DE102007046611A1 (de) * 2007-09-28 2009-04-02 Osram Opto Semiconductors Gmbh Lichtquelle mit Konversionselement und Lichtwellenleiter, Verfahren zur Herstellung der Lichtquelle und deren Verwendung
SI2235197T1 (sl) 2007-12-27 2017-10-30 Baxalta GmbH Procesi celične kulture
MX2010007344A (es) 2007-12-31 2010-11-09 Baxter Int Furina recombinante substancialmente libre de proteina animal y metodos para la produccion de la misma.
JP4458167B2 (ja) * 2008-01-11 2010-04-28 住友金属工業株式会社 熱間塑性加工用潤滑剤を用いる継目無管製造における外面潤滑方法
US20110086813A1 (en) 2008-03-19 2011-04-14 Gad Glaser Compounds for treating bacterial infections
MX2010011356A (es) * 2008-04-17 2010-11-09 Wyeth Llc Metodos para la produccion mejorada de proteinas morfogeneticas de hueso.
US8486699B2 (en) * 2008-05-23 2013-07-16 The United States Of America As Represented By The Secretary Of Agriculture Immortal unipotent porcine PICM-19H and PICM-19B stem cell lines
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
WO2011014838A1 (en) * 2009-07-31 2011-02-03 Baxter International Inc. Cell culture medium for adamts protein expression
CN103097522A (zh) 2010-07-08 2013-05-08 巴克斯特国际公司 在细胞培养物中生产重组adamts13的方法
TWI408228B (zh) 2010-10-29 2013-09-11 Univ Nat Chunghsing 用於生產一標的蛋白質的核酸建構物、重組型載體以及方法

Also Published As

Publication number Publication date
IL286298A (en) 2021-10-31
EA201792340A3 (ru) 2018-07-31
NZ605403A (en) 2014-10-31
CA2805557A1 (en) 2012-01-12
PL2591094T3 (pl) 2019-02-28
WO2012006591A1 (en) 2012-01-12
EA202090220A2 (ru) 2020-05-31
EP4628093A2 (en) 2025-10-08
KR20130091329A (ko) 2013-08-16
EP4628093A3 (en) 2025-12-10
IL273304A (en) 2020-04-30
EA029503B1 (ru) 2018-04-30
AU2015207811A1 (en) 2015-08-20
CA2804275A1 (en) 2012-01-12
US11780904B2 (en) 2023-10-10
SI3064508T2 (sl) 2023-05-31
JP6138683B2 (ja) 2017-05-31
AU2022200035A1 (en) 2022-01-20
US20150018525A1 (en) 2015-01-15
EP3909977A1 (en) 2021-11-17
AU2020203565B2 (en) 2021-09-30
DK2591094T3 (en) 2018-11-26
DK2590998T3 (en) 2018-02-12
EP3626736B1 (en) 2025-06-11
HUE038193T2 (hu) 2018-09-28
SI2590998T1 (en) 2018-06-29
US20150056657A1 (en) 2015-02-26
IL286298B (en) 2022-08-01
CN107286235A (zh) 2017-10-24
EP3392271B1 (en) 2021-05-05
ES2761692T3 (es) 2020-05-20
HUE046443T2 (hu) 2020-03-30
IL255327B (en) 2020-04-30
IL223929A (en) 2017-11-30
EA201390082A1 (ru) 2013-06-28
EA202090220A3 (ru) 2020-08-31
EP2590998B1 (en) 2017-11-15
TR201815211T4 (tr) 2018-11-21
KR20180130587A (ko) 2018-12-07
NZ605404A (en) 2014-08-29
PT2591094T (pt) 2018-11-20
SG10201809632XA (en) 2018-12-28
TWI670073B (zh) 2019-09-01
MX339632B (es) 2016-06-02
CO6690745A2 (es) 2013-06-17
BR112013000515B1 (pt) 2021-11-03
KR20180099922A (ko) 2018-09-05
PT2590998T (pt) 2018-02-13
EP2591094B1 (en) 2018-09-05
ES2694518T3 (es) 2018-12-21
CO6680636A2 (es) 2013-05-31
WO2012006594A1 (en) 2012-01-12
DK3626736T3 (da) 2025-08-18
EA035147B1 (ru) 2020-05-06
JP2016025873A (ja) 2016-02-12
CN103097409A (zh) 2013-05-08
CN103097522A (zh) 2013-05-08
AU2015207811B2 (en) 2017-10-19
US20190085052A1 (en) 2019-03-21
TWI646972B (zh) 2019-01-11
MX2013000165A (es) 2013-06-05
PL3064508T5 (pl) 2024-04-08
FI3626736T3 (fi) 2025-08-22
AU2018200206A1 (en) 2018-04-05
TW201206953A (en) 2012-02-16
HRP20192089T1 (hr) 2020-03-20
KR102007773B1 (ko) 2019-08-06
KR101924120B1 (ko) 2018-11-30
CN108060154A (zh) 2018-05-22
SI3626736T1 (sl) 2025-10-30
AU2018200206B2 (en) 2020-05-28
PT3064508T (pt) 2019-12-05
IL273304B (en) 2021-09-30
JP5953502B2 (ja) 2016-07-20
EP3626736A1 (en) 2020-03-25
TW201637665A (zh) 2016-11-01
US20120034674A1 (en) 2012-02-09
AU2020203565A1 (en) 2020-06-18
ES3037386T3 (en) 2025-10-01
HRP20192089T4 (hr) 2023-04-28
MX2013000166A (es) 2013-06-05
US20180044405A1 (en) 2018-02-15
HUE11738351T2 (hu) 2019-03-28
EP3392271B8 (en) 2021-06-16
DK3064508T3 (da) 2019-11-25
JP2017217004A (ja) 2017-12-14
ES2664392T3 (es) 2018-04-19
EA035066B1 (ru) 2020-04-23
EP2591094A1 (en) 2013-05-15
TWI609890B (zh) 2018-01-01
PT3626736T (pt) 2025-08-11
PL2590998T3 (pl) 2018-05-30
US8852888B2 (en) 2014-10-07
SG186936A1 (en) 2013-02-28
KR101894604B1 (ko) 2018-09-03
EA202090067A3 (ru) 2020-07-31
PL3392271T3 (pl) 2021-11-15
US9458222B2 (en) 2016-10-04
KR102027991B1 (ko) 2019-10-02
HRP20180136T1 (hr) 2018-04-06
EP3064508B1 (en) 2019-08-28
EA202090067A2 (ru) 2020-04-30
US10100099B2 (en) 2018-10-16
JP2013533748A (ja) 2013-08-29
TWI617575B (zh) 2018-03-11
ES2761692T5 (es) 2023-07-05
BR112013000515A2 (pt) 2016-05-17
IL223930A (en) 2017-01-31
PL3064508T3 (pl) 2020-02-28
HRP20250948T1 (hr) 2025-10-10
ES2875772T3 (es) 2021-11-11
EP2590998A1 (en) 2013-05-15
IL255327A0 (en) 2017-12-31
EP3392271A1 (en) 2018-10-24
AU2011274467B2 (en) 2015-01-15
TW201900207A (zh) 2019-01-01
US9834591B2 (en) 2017-12-05
DK3064508T4 (da) 2023-04-11
BR112013000512A2 (pt) 2016-05-17
JP6284919B2 (ja) 2018-02-28
US10822394B2 (en) 2020-11-03
AU2011274467A1 (en) 2013-01-24
SI3064508T1 (sl) 2019-12-31
MX353409B (es) 2018-01-11
US20170008948A1 (en) 2017-01-12
JP2013538046A (ja) 2013-10-10
HRP20181657T1 (hr) 2019-03-08
AU2011274470A1 (en) 2013-01-24
FI3064508T4 (fi) 2023-04-25
KR20130091328A (ko) 2013-08-16
SG186935A1 (en) 2013-02-28
EA201792340A2 (ru) 2018-02-28
US20210115110A1 (en) 2021-04-22
EP3064508A1 (en) 2016-09-07
SI2591094T1 (sl) 2018-12-31
US20120035110A1 (en) 2012-02-09
US9409971B2 (en) 2016-08-09
TW201204744A (en) 2012-02-01
EA201390080A1 (ru) 2013-06-28
AU2011274470B2 (en) 2015-08-13
EP3064508B2 (en) 2023-03-15

Similar Documents

Publication Publication Date Title
IL286298A (en) A method to generate high molecular weight substituted vwf in cell culture
IL288509A (en) Mammalian cell culture
ZA201707452B (en) Cell culture compositions and methods for polypeptide production
GB2491209B (en) Solar cell and method for producing same
ZA201404439B (en) Novel solar modules, supporting layer stacks and methods of fabricating thereof
SI2459697T1 (sl) Metoda proizvodnje polipeptida ali virusa interesa v kontinuirani celični kulturi
GB201113641D0 (en) Cell culture support and cell culture method
GB201020075D0 (en) Mammalian cell transformation method
IL225348A0 (en) A method for obtaining a cell population rich in desired cells
GB201120446D0 (en) Mammalian cell transformation method